Apr 15 |
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
|
Apr 15 |
Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
|
Apr 10 |
All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy
|
Apr 10 |
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
|
Apr 9 |
Innate Pharma Announces Its Participation in Upcoming Investor Conference
|
Apr 5 |
Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F
|
Mar 22 |
Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript
|
Mar 21 |
Innate Pharma S.A. (IPHA) Q4 2023 Earnings Call Transcript
|
Mar 21 |
Innate Pharma GAAP EPS of -€0.09, revenue of €61.64M
|
Mar 21 |
Innate Pharma Reports Full Year 2023 Financial Results and Business Update
|